Skip to main
DMTK
DMTK

DermTech Inc (DMTK) Stock Forecast & Price Target

DermTech Inc (DMTK) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 17%
Buy 50%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

DermTech is experiencing significant revenue growth, primarily driven by a year-on-year increase in the average selling price (ASP) per test, which rose by 55% from the previous year. This growth is a result of DermTech's strategic focus on expanding reimbursed testing volumes and improving the onboarding process for new paying customers. Additionally, prospective publication of the TRUST 2 study and subsequent reengagement with national payers, coupled with recent positive coverage decisions by certain Blues Plans, are expected to further elevate the ASP, enhancing DermTech's long-term revenue prospects.

Bears say

DermTech is facing a potential decline in business due to a projected decrease in order volumes and unique ordering clinicians in the near future. The company's financial outlook is also concerning as it expects to burn $55M to $60M annually. Furthermore, DermTech's stock could be at risk of material multiple compression if it fails to meet market expectations or if overall market sentiment turns against growth stocks.

DermTech Inc (DMTK) has been analyzed by 6 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 50% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DermTech Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DermTech Inc (DMTK) Forecast

Analysts have given DermTech Inc (DMTK) a Buy based on their latest research and market trends.

According to 6 analysts, DermTech Inc (DMTK) has a Buy consensus rating as of Jul 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DermTech Inc (DMTK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.